Jade Biosciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a JBIO research report →
About the company
Jade Biosciences, Inc. operates as a biotechnology enterprise, primarily focused on pioneering superior therapeutic solutions for significant unmet medical requirements in autoimmune disorders. Its leading development candidate, JADE-001, specifically targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway, aiming to treat immunoglobulin A (IgA) nephropathy.
- CEO
- Tom Frohlich
- IPO
- 2025
- Employees
- 50
- HQ
- Waltham, MA, US
Price Chart
- Market Cap
- $701.78M
- P/E
- -7.37
- P/S
- 0.00
- P/B
- 4.19
- EV/EBITDA
- -5.00
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -51.34%
- ROIC
- -44.96%
- Revenue
- $0 · 0.00%
- Net Income
- $-127,410,000 · -82.99%
- EPS
- $-4.06 · 95.24%
- Op Income
- $-113,542,000
- FCF YoY
- -33.27%
- 52W High
- $28.00
- 52W Low
- $6.67
- 50D MA
- $21.42
- 200D MA
- $15.29
- Beta
- 1.43
- Avg Volume
- 992.64K
Get TickerSpark's AI analysis on JBIO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 25, 26 | Eisner Mark | other | 47,675 |
| Jun 25, 26 | Eisner Mark | other | 0 |
| Jun 9, 26 | CAIN CHRISTOPHER W. | other | 34,843 |
| Jun 9, 26 | DOBMEIER ERIC | other | 34,843 |
| Jun 9, 26 | Klein Lawrence Otto | other | 34,843 |
| Jun 9, 26 | Lavelle Erin | other | 34,843 |
| Jun 9, 26 | Fairmount Funds Management LLC | other | 34,843 |
| Feb 12, 26 | Dahms Bradford D. | other | 226,875 |
| Feb 12, 26 | Dahms Bradford D. | other | 37,813 |
| Feb 12, 26 | Balta Elizabeth | other | 168,750 |
Our JBIO coverage
Recent articles, reports, and earnings notes.
No research on JBIO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate JBIO report →Similar companies
Peers in the same neighborhood.